In short
Clinical trials investigating Zopiclone are studying its role in a patient group with benzodiazepine dependence and related psychiatric or addiction disorders. These studies focus on outcomes such as changes in benzodiazepine use and compare Zopiclone with other study treatments or placebo. They help show how Zopiclone is being evaluated in real research settings.
Key points
- Clinical trials investigating Zopiclone in the provided data are focused on people with benzodiazepine dependence and related psychiatric or addiction conditions. The main study is an authorised Phase 4 interventional trial with 93 participants. It measures change in total benzodiazepine use, using diazepam-equivalent milligrams as the main outcome. The trial compares study treatments in a randomised setting over about 62 to 64 days. This research is aimed at understanding treatment effects in a real patient group. The data provided include one main trial and do not describe a broad set of studies.
Trial overview
The provided clinical trial data include one study that mentions Zopiclone as one of the study drugs. This trial is titled “BACLOFEN FOR IMPROVING BENZODIAZEPINE TITRATION IN BENZODIAZEPINE DEPENDENCE. BABET,” and it is an interventional study in Phase 4. The study is authorised and plans to enroll 93 participants.
Who the trial is for
The trial targets people with psychiatric disorders and addictology conditions, which means mental health and addiction-related problems. The brief summary says the study is designed for patients with benzodiazepine use disorder, a condition where benzodiazepine use causes harm or is hard to control. This means the study is not aimed at healthy volunteers, but at a patient group with dependence-related needs.
Study design and treatment groups
This is an interventional trial, which means the researchers assign study treatments and then measure the results. The intervention list includes baclofen, ZOLPIDEM, ZOPICLONE, cellulose microcristalline, and placebo-like entries shown as “-” in the record. The trial summary states that baclofen is being compared to placebo to see whether it helps reduce benzodiazepine doses.
In the source data, randomisation is used, which means participants are assigned by chance to study groups. This helps make the comparison between groups fairer and reduces bias, which is when results are influenced by the way groups are chosen rather than by the treatment itself.
What is being measured
The main outcome is the difference in total benzodiazepine use, measured in mg-diazepam, between the 28 days before study entry and the last 28 days before the final visit on Day 62/64 of randomisation. Diazepam-equivalent measurement is a way to compare different benzodiazepines using one common scale. This outcome shows whether the study treatment helps lower benzodiazepine consumption over time.
The study brief summary says the goal is to assess the efficacy of baclofen compared with placebo in reducing benzodiazepine doses in patients with benzodiazepine use disorder. Although Zopiclone appears in the intervention list, the source data do not describe Zopiclone as the main study question by itself.
Trial status and size
The trial status is listed as Authorised, meaning it has approval to proceed in the setting described in the record. The planned enrollment is 93 participants, which is the number of people the researchers expect to include. The study is in Phase 4, so it is being done in a later stage of clinical research rather than an early testing stage.
Why this research matters
This trial is important because it studies treatment approaches for people who have difficulty reducing benzodiazepine use. By measuring changes in benzodiazepine consumption over a defined time period, the researchers can learn whether the study approach helps patients lower use more successfully. The presence of Zopiclone in the intervention list shows that it is part of the clinical research setting described in the record.